Pyxis Oncology
Mr. Thomas Civik most recently served as President and Chief Executive Officer of Five Prime Therapeutics until its acquisition by Amgen for $1.9 billion in April 2021. He was previously Chief Commercial Officer at Foundation Medicine, delivering significant growth during his tenure and launching the first ever FDA-approved pan-cancer comprehensive genomic test.
Thomas held various roles over a 17-year career at Genentech, including responsibility for several important therapies such as Avastin, Tecentriq, Alecensa and Tarceva. Mr. Civik earned a B.A. from St. Norbert College, and an M.B.A. from Northwestern University Kellogg School of Management.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Pyxis Oncology
2 followers
Pyxis Oncology is advancing a differentiated portfolio of potent biologics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to help patients suffering from difficult-to-treat cancers.